Endocrinology

Top Medical News
Roshini Claire Anthony, 13 hours ago

The efficacy of lanifibranor in reducing histological markers of non-alcoholic steatohepatitis (NASH) is comparable in patients with and without type 2 diabetes (T2D), according to the phase IIb NATIVE study presented as a poster at AASLD 2020.

Yesterday
High manganese intake from foods and drinks lowers the risk of developing type 2 diabetes in women but not in men, a study has found.
Yesterday
Body mass index (BMI) values that are above average and the development of overweight from childhood to adulthood are risk factors for gestational hypertension and pre-eclampsia, but normalizing BMI from childhood to conception reduces such risks, according to a study.
Yesterday
Accelerometer-assessed moderate-to-vigorous physical activity (MVPA) at baseline shows an inverse relationship with incident diabetes among individuals aged ≥50 years, a recent study involving a US Hispanic/Latino population has found.
Yesterday
Patients with acute ischaemic stroke undergoing endovascular treatment are at heightened risk of poor functional outcome and symptomatic intracranial haemorrhage (sICH) in the presence of hyperglycaemia at admission, a study has found.
Stephen Padilla, 2 days ago
Rosacea, a chronic inflammatory cutaneous disorder associated with multiple systemic illnesses, is associated with hypertension and dyslipidaemia but not with ischaemic heart disease (IHD), stroke, or diabetes, results of a systematic review and meta-analysis have shown.
Audrey Abella, 2 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.
Special Reports
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Roshini Claire Anthony, 05 Nov 2020

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.

26 Oct 2020

An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]

Pank Jit Sin, 02 Sep 2020
The most recent report by the National Health and Morbidity Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with consistent, unrelenting efforts by stakeholders and policymakers, the figures for NCDs continue to climb. MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in the country and to obtain his thoughts on the ramifications of the findings. 
11 Aug 2020
In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.
09 Jul 2020
In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.
29 Jun 2020
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.
Conference Reports
Elaine Soliven, 27 Oct 2020
Ultra rapid lispro (URLi) was noninferior to lispro in reducing HbA1c levels in adults with type 1 diabetes (T1D), according to the PRONTO-Pump-2* study presented at EASD 2020.
Roshini Claire Anthony, 21 Oct 2020

NT-814, an oral, non-hormonal dual neurokinin 1,3 receptor antagonist may reduce the frequency of hot flashes, while improving quality of life (QoL) and sleep in postmenopausal women, according to results of the phase IIb SWITCH-1 trial presented at NAMS 2020.

Roshini Claire Anthony, 19 Oct 2020

Women who experience two or more moderate or severe menopausal symptoms may have an elevated risk of cardiovascular disease (CVD) or strokes, according to a study presented at NAMS 2020.

Pearl Toh, 15 Oct 2020
Cycling was associated with reduced risk for both all-cause and cardiovascular (CV) mortality in people with diabetes, according to a study presented at EASD 2020 Meeting — suggesting that cycling could be encouraged as an activity to prevent deaths in this population who are known to have a higher mortality risk than the general public.
Audrey Abella, 15 Oct 2020
Fast eating increases post-prandial glucose (PPG) concentration and glycaemic excursion in young, healthy women without diabetes, an interventional study has shown, thus underscoring the role of eating speed in the development of type 2 diabetes (T2D) and obesity.
Elaine Soliven, 15 Oct 2020

Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.

Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download